No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - UK pharma giant GSK and its partner Spero Therapeutics on Wednesday said it had ended a late-stage trial of an experimental drug for complicated urinary tract infections early after it met its main target.
The decision comes after a recommendation from an independent committee that completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial.
Both firms said the oral drug, known as tebipenem Hbr, was found to be equal to an existing intravenous treatment in hospitalised adult patients.
GSK said it planned to work with US regulatory authorities to include the data as part of a filing in the second half of the year.
Reporting by Frank Prenesti for Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.